N-9 efficacy study
This article was originally published in The Tan Sheet
Risk of HIV-1 infection was "especially high" in women who used nonoxynol-9 more than 3.5 times per day due to "an increasing frequency of lesions" caused by the spermicide, researchers report in Sept. 28 Lancet. Lut Van Damme, MD, Institute of Tropical Medicine, Antwerp, Belgium, et al., found that at low-frequency use, N-9 had no effect on HIV-1 infection. Researchers randomized 892 sex workers in South Africa, Thailand, Benin and Ivory Coast to either 3.5% N-9 gel or placebo; investigators conclude the drug "no longer has a part to play in HIV-1 prevention"...
You may also be interested in...
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.